Clues Pointing TO This Diagnosis

Symmetrical, bilateral joint involvement (both hands at the same time) — symmetric small-joint polyarthritis is the classic pattern of RA
MCP (knuckle) and wrist involvement — RA characteristically targets the metacarpophalangeal and wrist joints
Prolonged morning stiffness lasting hours — morning stiffness of 30 minutes or longer points to an inflammatory rather than mechanical arthritis
Swollen, red knuckles with difficulty making a fist — visible synovitis (effusion, erythema, warmth) is a hallmark of RA
Middle-aged woman (age 48) — RA disproportionately affects women and commonly presents in this age range
Systemic fatigue distinct from ordinary tiredness — constitutional symptoms accompany the systemic inflammation of RA
Symptoms persisting well beyond a few weeks (since autumn) — inflammatory arthritis lasting 6 weeks or more supports RA over a transient/viral arthritis
Positive rheumatoid factor — a supportive serologic marker included in the classification criteria
High-titer anti-CCP (ACPA) antibody — highly specific for RA and carries prognostic weight for erosive disease
Bony erosions on x-ray — erosive change reflects the destructive synovitis/pannus of RA
Synovitis with power Doppler signal on ultrasound — imaging confirmation of active inflammatory synovitis

Why It's NOT the Similar Diseases

NOT osteoarthritis — OA causes brief (<30 min) morning stiffness, targets DIPs/weight-bearing joints, and lacks warmth, positive anti-CCP, and an acute-phase response; Helen has prolonged stiffness, MCP/wrist synovitis, and positive serology
NOT systemic lupus erythematosus — SLE causes a non-erosive arthritis with positive ANA/anti-dsDNA and multisystem features (rash, nephritis); Helen has erosive disease with high-titer anti-CCP
NOT gout/crystal arthritis — gout is typically acute, monoarticular, and asymmetric with hyperuricemia; Helen has chronic, symmetric small-joint polyarthritis
NOT psoriatic arthritis — PsA often involves DIPs, is frequently asymmetric, and is associated with psoriasis and nail changes, none of which are present here
NOT viral (e.g., parvovirus) arthritis — viral arthritis usually resolves within a few weeks; Helen's symptoms have persisted for months with erosions and positive anti-CCP

Differential Diagnosis List

Osteoarthritis — ruled out by prolonged morning stiffness, MCP/wrist synovitis, elevated markers, and positive anti-CCP
Systemic lupus erythematosus — ruled out by erosive joint disease and high-titer anti-CCP rather than ANA/anti-dsDNA with non-erosive arthritis
Gout/crystal arthritis — ruled out by chronic symmetric polyarticular pattern rather than acute monoarticular attacks
Psoriatic arthritis — ruled out by absence of psoriasis, nail changes, and DIP/asymmetric involvement
Viral arthritis — ruled out by months-long persistence with erosions and positive serology

Key Distinguishing Test

RA is diagnosed clinically (there are no formal diagnostic criteria), supported by serology and imaging; anti-CCP (ACPA) antibody is the most specific blood test—about 95% specific—and a high-titer positive result in a patient with symmetric small-joint synovitis strongly supports RA and predicts erosive disease.
Rheumatoid factor and elevated CRP/ESR are supportive, and the 2010 ACR/EULAR classification criteria (joint involvement, serology, acute-phase reactants, symptom duration ≥6 weeks) help identify early RA.

Board Note

Suspect RA in symmetric small-joint (MCP, PIP, wrist) polyarthritis with morning stiffness ≥30 minutes and constitutional symptoms; order CBC, CMP, CRP, ESR, RF, and anti-CCP, and refer early to rheumatology because early treatment prevents joint damage in up to ~90% of patients
Anti-CCP is more specific than RF and better predicts erosive/radiographic progression
Methotrexate is the first-line anchor DMARD, given weekly with folic acid; current ACR/EULAR guidance uses a treat-to-target strategy aiming for remission or low disease activity
DMARDs are disease-modifying (they slow joint destruction), not merely analgesic, and clinical improvement can take about 6 weeks; escalate to a biologic or targeted synthetic DMARD (e.g., TNF or JAK inhibitor) added to methotrexate if the target is not met
All DMARDs increase infection risk—keep vaccinations up to date—and monitor methotrexate for hepatotoxicity and cytopenias; it is teratogenic and contraindicated in pregnancy
Address cardiovascular risk factors, since RA carries an increased risk of cardiovascular disease
The materials below are grounded in current sources: the 2026 AAO Primary Open-Angle Glaucoma Preferred Practice Pattern, the JAMA glaucoma reviews, the Lancet glaucoma reviews, the LiGHT trial, and the 2022 USPSTF glaucoma screening statement.
─── PART 1 — DECODER SHEET ───

“Helen’s Story”